PR Newswire TechnologyCodex · 实盘不做把握 7/10
北京时间·🕒 发布 20:55:00时区推断·⟳ 抓取 20:55:15·⚡ 决策 08-05 22:07:32 +1h12m·83.1 天前
纽交所盘前日更提及指数新高、Expedition融资、Zeta财报访谈和开闭市敲钟安排
这条PR Newswire内容本质是纽交所盘前日更和访谈预告，不是Zeta Global（ZETA.US）财报首发或新增指引。
📄 原文PR Newswire Technology↗ 原文
NYSE Content Update: Expedition Therapeutics Secures $115 Million Series B
NYSE issues a pre-market daily advisory direct from the trading floor. NEW YORK, Aug. 5, 2026 /PRNewswire/ -- The New Y…
不做 Zeta Global（ZETA.US）
不做：NYSE日更不是Zeta财报首发，真正财报利好已于2026-08-04官方发布且股价盘中已涨约14.5%，当前追买剩余edge不足。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
消息传播链
- Zeta已先行发布2Q26财报和上调全年指引，构成真正的公司级信息源。
- NYSE盘前日更提及Zeta CEO将上NYSE Live解读Q2财报，但没有披露新的财务数字或指引。市场反应:截至约10:05 ET，ZETA.US报27.77美元，较前收涨14.47%。
关键理由
- 这条PR Newswire内容本质是纽交所盘前日更和访谈预告，不是Zeta Global（ZETA.US）财报首发或新增指引。
- Zeta Global（ZETA.US）2Q26官方财报已在2026-08-04发布：收入4.43亿美元、全年收入指引中点上调3300万美元，本条只是二次提及。
- Zeta Global（ZETA.US）当前盘中已涨约14.5%、20日涨约27%，本次具体财报催化已被市场即时重定价，继续追买缺少剩余edge。
主要风险
- 若Zeta财报后机构持续上修，股价可能延续动量，但这需要新的交易信号而不是用NYSE日更追高。
- Expedition Therapeutics为私营融资与临床进展信息，当前没有可直接交易标的。
工具调用 · 历史记录,结果未知(5 种)
- stock_quote · 结果未知
- search_processed_events · 结果未知
- kb_search · 结果未知
- search_case_library · 结果未知
- kb_fetch_document · 结果未知
原文全文
展开原文 · 1,341 字
NYSE issues a pre-market daily advisory direct from the trading floor.
NEW YORK, Aug. 5, 2026 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins.
Ashley Mastronardi delivers the pre-market update on August 5th
- The Dow Jones Industrial Average and S&P 500 will look to build off fresh records on hopes of a deal in the Middle East.
- The Dow surpassed 54,000 for the first time ever.
- The S&P 500 clinched its first-ever close above 7,700.
- Expedition Therapeutics Founder & CEO Yi Larson will join NYSE Live following her firm's latest funding round.
- The company says the first patients have been dosed in its Phase 2 clinical trial for EXPD-101, a next-gen treatment for COPD.
- Zeta Global (NYSE: ZETA) CEO David Steinberg will join NYSE Live to deliver the biggest takeaways from the company's Q2 earnings report.
- The firm says it posted its 20th straight 'beat-and-raise' quarter and achieved the 'Rule of 64.'
Opening Bell
AB InBev (NYSE: BUD) rings the NYSE Opening Bell
Closing Bell
Blend (NYSE: BLND) celebrates its 5th anniversary of listing
For market insights, IPO activity, and today's opening bell, download the NYSE TV App: TV.NYSE.com
SOURCE New York Stock Exchange
NEW YORK, Aug. 5, 2026 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins.
Ashley Mastronardi delivers the pre-market update on August 5th
- The Dow Jones Industrial Average and S&P 500 will look to build off fresh records on hopes of a deal in the Middle East.
- The Dow surpassed 54,000 for the first time ever.
- The S&P 500 clinched its first-ever close above 7,700.
- Expedition Therapeutics Founder & CEO Yi Larson will join NYSE Live following her firm's latest funding round.
- The company says the first patients have been dosed in its Phase 2 clinical trial for EXPD-101, a next-gen treatment for COPD.
- Zeta Global (NYSE: ZETA) CEO David Steinberg will join NYSE Live to deliver the biggest takeaways from the company's Q2 earnings report.
- The firm says it posted its 20th straight 'beat-and-raise' quarter and achieved the 'Rule of 64.'
Opening Bell
AB InBev (NYSE: BUD) rings the NYSE Opening Bell
Closing Bell
Blend (NYSE: BLND) celebrates its 5th anniversary of listing
For market insights, IPO activity, and today's opening bell, download the NYSE TV App: TV.NYSE.com
SOURCE New York Stock Exchange
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。